https://www.selleckchem.com/pr....oducts/perhexiline-m
Effective treatments for patients with cholangiocarcinoma after progression on gemcitabine-based chemotherapy are urgently needed. Mutations in the BRAF gene have been found in 5% of biliary tract tumours. The combination of dabrafenib and trametinib has shown activity in several BRAF -mutated cancers. We aimed to assess the activity and safety of dabrafenib and trametinib combination therapy in patients with BRAF -mutated biliary tract cancer. This study is part of an ongoing, phase 2, open-label, single-arm, multicentre, R
Like
Comment
Share
